Gentex Acquires Biometric Authentication Firm BioConnect

Reuters11-17
Gentex Acquires Biometric Authentication Firm BioConnect

Gentex Corporation has acquired Toronto-based BioConnect, a company specializing in biometric authentication solutions. BioConnect provides a multi-modal authentication software platform used in the security and access control industry, serving over 1,500 customers in sectors such as data storage, healthcare, financial services, education, and manufacturing. This acquisition brings together BioConnect's expertise with Gentex's existing biometric technology, including EyeLock, to form a new Security & Access Control team. The combined team aims to develop advanced biometric solutions for various industries, leveraging Gentex's engineering and manufacturing capabilities to expand into new markets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gentex Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9576280-en) on November 17, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment